Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Paysign Q3 2026 Results: Net Income $6.74M, Up 204.1% YoY

Paysign, Inc. reported significant growth for the nine months ended September 30, 2026, with total revenues increasing to $87.1 million compared to $59.3 million in the prior year, driven largely by a doubling of Pharma industry revenue. Net income for the nine-month period rose to $18.9 million, up from $6.2 million in 2025, reflecting improved operating leverage and higher interest income.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue30.821.6
Gross profit19.912.2
Profit before tax8.22.2
Net income6.72.2
EPS (diluted, $ a share)$0.11$0.04

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year+204.1%
Revenue, year on year+42.6%
Gross margin64.7%
Operating margin23.8%
Source

10-Q filed with the SEC, NASDAQ: PAYS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Paysign, Inc.: key numbers

Share price
$9.54Close, Nov 16
Market cap
$542M
Shares outstanding
56.85MLatest SEC cover page
Sector
Trade & Services
Industry
Services-Business Services, NECSIC 7389

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Paysign, Inc.

All →
4:06 PM ET 8-K
Financial Results

Paysign Financial Results

Paysign reported record third-quarter 2026 revenue of $30.8 million, a 43% increase year-over-year, driven by 110% growth in its Pharma patient affordability segment. The company's operating margin more than tripled to 23.8%, and GAAP net income rose to $6.74 million. Management raised full-year 2026 guidance for gross margin, net income, and Adjusted EBITDA while confirming its revenue outlook.

Term
Q3 2026

“This was a strong quarter, with patient affordability continuing to compound. We expanded to 167 active programs and increased the quarterly revenue per program by approximately 32% to $99,524. As that business becomes a larger share of our total revenue, we’re seeing gross margin and operating margin expand together, which is translating into higher Adjusted EBITDA.”

Mark Newcomer, President and CEO

“Patient affordability is driving our business, and we are seeing demand and momentum continue to build. Plasma remains an important part of our business, and our experience as one of the leading processors in the industry has given us the insights to understand the challenges plasma centers face.”

Mark Newcomer, President and CEO
9:00 PM ET Form 4
Insider Selling

Paysign CEO Mark Newcomer Sells $767K of Stock

Mark Newcomer, CEO, sold 50,000 shares of Paysign, Inc. at $15.34 a share, worth $767K in total on Oct 9, 2026. Shares held after the trade: 9,113,002 (-0.5%).

Value
$767K
Shares
50,000
Price
$15.34
Role
CEO
Holding change
-0.5%
Trade date
Oct 9, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.